Mitochondrial dysfunction and α -synuclein synaptic pathology in Parkinson's disease: Who's on first?

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Zaltieri, Michela ^a   Longhena, Francesca ^a   Pizzi, Marina ^a,b   Missale, Cristina ^a   Spano, Pierfranco ^a,b   Bellucci, Arianna ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 84928485187     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/108029     Document Type: Review

References (136)

1. M. Spatola and C. Wider, "Genetics of Parkinsons disease: the yield," Parkinsonism and Related Disorders, vol. 20, supplement 1, pp. S35-S38, 2014.
2. S. Fujioka and Z. K. Wszolek, "Clinical aspects of familial forms of frontotemporal dementia associated with parkinsonism," Journal of Molecular Neuroscience, vol. 45, no. 3, pp. 359-365, 2011.
3. C. Perier, J. Bove, and M. Vila, "Mitochondria and programmed cell death in Parkinsons disease: apoptosis and beyond," Antioxidants and Redox Signaling, vol. 16, no. 9, pp. 883-895, 2012.
4. M. A. Lynch-Day, K. Mao, K. Wang,M. Zhao, and D. J. Klionsky, "The role of autophagy in Parkinsons disease," Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 4,Article IDa009357, 2012.
5. G. Mercado, P. Valdes, and C. Hetz, "An ERcentric view of Parkinsons disease," Trends in Molecular Medicine, vol. 19, no. 3, pp. 165-175, 2013.
6. C. S. Chan, J. N. Guzman, E. Ilijic et al. , "Rejuvenation protects neurons in mouse models of Parkinsons disease," Nature, vol. 447, no. 7148, pp. 1081-1086, 2007.
7. A. Camilleri and N. Vassallo, "The centrality of mitochondria in the pathogenesis and treatment of Parkinsons disease," CNS Neuroscience andTherapeutics, vol. 20, no. 7, pp. 591-602, 2014.
8. K. Vekrellis, M. Xilouri, E. Emmanouilidou, and L. Stefanis, "Inducible over-expression of wild type α-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death," Journal of Neurochemistry, vol. 109, no. 5, pp. 1348-1362, 2009.
9. A. Bellucci, L. Navarria, M. Zaltieri et al. , "Induction of the unfolded protein response by α-synuclein in experimental models of Parkinsons disease," Journal of Neurochemistry, vol. 116, no. 4, pp. 588-605, 2011.
10. D. I. Dryanovski, J. N. Guzman, Z. Xie et al. , "Calciumentry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons,"The Journal of Neuroscience, vol. 33, no. 24, pp. 10154-10164, 2013.
11. H. Braak, K. Del Tredici, U. Rub, R. A. I. de vos, E. N. H. Jansen Steur, and E. Braak, "Staging of brain pathology related to sporadic Parkinsons disease," Neurobiology of Aging, vol. 24, no. 2, pp. 197-211, 2003.
12. H. Braak, E. Ghebremedhin, U. Rub, H. Bratzke, and K. del Tredici, "Stages in the development of Parkinsons diseaserelated pathology," Cell and Tissue Research, vol. 318, no. 1, pp. 121-134, 2004.
13. K. Del Tredici,U. Rub, R. A. I. deVos, J. R. E. Bohl, and H. Braak, "Where does Parkinson disease pathology begin in the brain?" Journal of Neuropathology and Experimental Neurology, vol. 61, no. 5, pp. 413-426, 2002.
14. C. M. Lema Tome, T. Tyson, N. L. Rey, S. Grathwohl, M. Britschgi, and P. Brundin, "Inflammation and α-synucleins prion-like behavior in Parkinsons disease-is there a link?" Molecular neurobiology, vol. 47, no. 2, pp. 561-574, 2013.
15. O. Anichtchik, L. Calo, and M. G. Spillantini, "Synaptic dysfunction in synucleinopathies," CNSandNeurologicalDisorders-Drug Targets, vol. 12, no. 8, pp. 1094-1100, 2013.
16. S. Orimo, T. Uchihara, A. Nakamura et al. , "Axonal alphasynuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinsons disease," Brain, vol. 131, no. 3, pp. 642-650, 2008.
17. Z. H. Sheng, "Mitochondrial trafficking and anchoring in neurons: new insight and implications," Journal of Cell Biology, vol. 204, no. 7, pp. 1087-1098, 2014.
18. D. J. Surmeier, J. N. Guzman, J. Sanchez-Padilla, and P. T. Schumacker, "The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinsons disease," Neuroscience, vol. 198, pp. 221-231, 2011.
19. G. W. Arbuthnott and J. Wickens, "Space, time and dopamine," Trends in Neurosciences, vol. 30, no. 2, pp. 62-69, 2007.
20. C. J. Wilson and J. C. Callaway, "Coupled oscillator model of the dopaminergic neuron of the substantia nigra," Journal of Neurophysiology, vol. 83, no. 5, pp. 3084-3100, 2000.
21. B. Halliwell, "Oxidative stress and neurodegeneration: where are we now?" Journal of Neurochemistry, vol. 97, no. 6, pp. 1634-1658, 2006.
22. S. J. Chinta and J. K. Andersen, "Redox imbalance in Parkinsons disease," Biochimica et Biophysica Acta: General Subjects, vol. 1780, no. 11, pp. 1362-1367, 2008.
23. S. J. Kish, J. J. Gilbert, L. J. Chang, L. Mirchandani, K. Shannak, and O. Hornykiewicz, "Brain neurotransmitter abnormalities in neuronal intranuclear inclusion body disorder," Annals of Neurology, vol. 17, no. 4, pp. 405-407, 1985.
24. J. J. Palacino, D. Sagi, M. S. Goldberg et al. , "Mitochondrial dysfunction and oxidative damage in parkin-deficient mice," The Journal of Biological Chemistry, vol. 279, no. 18, pp. 18614-18622, 2004.
25. L. Parisiadou, C. Xie, J. C. Hyun et al. , "Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis," The Journal of Neuroscience, vol. 29, no. 44, pp. 13971-13980, 2009.
26. S. Schmidt, B. Linnartz, S. Mendritzki et al. , "Genetic mouse models for Parkinsons disease display severe pathology in glial cell mitochondria," Human Molecular Genetics, vol. 20, no. 6, pp. 1197-1211, 2011.
27. A. Trancikova, E. Tsika, and D. J. Moore, "Mitochondrial dysfunction in genetic animal models of Parkinsons disease," Antioxidants and Redox Signaling, vol. 16, no. 9, pp. 896-919, 2012.
28. M. C. Meulener, K. Xu, L. Thompson, H. Ischiropoulos, and N. M. Bonini, "Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12517-12522, 2006.
29. E. H. Norris, B. I. Giasson, H. Ischiropoulos, and V. M.-Y. Lee, "Effects of oxidative and nitrative challenges on α-synuclein fibrillogenesis involve distinctmechanisms of protein modifications," Journal of Biological Chemistry, vol. 278, no. 29, pp. 27230-27240, 2003.
30. A. A. Dijkstra, P. Voorn, H. W. Berendse,H. J. Groenewegen,A. J. Rozemuller, and W. D. van de Berg, "Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinsons disease," Movement Disorders, vol. 29, no. 10, pp. 1244-1251, 2014.
31. W. J. Schulz-Schaeffer, "The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinsons disease and Parkinsons disease dementia," Acta Neuropathologica, vol. 120, no. 2, pp. 131-143, 2010.
32. R. Hilker, K. Schweitzer, S. Coburger et al. , "Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity," Archives of Neurology, vol. 62, no. 3, pp. 378-382, 2005.
33. Y. Ouchi, E. Yoshikawa, Y. Sekine et al. , "Microglial activation and dopamine terminal loss in early Parkinsons disease," Annals of Neurology, vol. 57, no. 2, pp. 168-175, 2005.
34. S. Nikolaus, C. Antke, M. Beu et al. , "In-vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT," Nuclear Medicine Communications, vol. 28, no. 3, pp. 207-213, 2007.
35. C. Pifl, A. Rajput, H. Reither et al. , "Is Parkinsons disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum," The Journal of Neuroscience, vol. 34, no. 24, pp. 8210-8218, 2014.
36. A. Abeliovich, Y. Schmitz, I. Farinas et al. , "Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system," Neuron, vol. 25, no. 1, pp. 239-252, 2000.
37. M. Lundblad, M. Decressac, B. Mattsson, and A. Bjorklund, "Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 9, pp. 3213-3219, 2012.
38. E. Rockenstein, S. Nuber, C. R. Overk et al. , "Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and neuronal degeneration in vivo," Brain, vol. 137, no. 5, pp. 1496-1513, 2014.
39. K. J. Spinelli, J. K. Taylor, V. R. Osterberg et al. , "Presynaptic alpha-synuclein aggregation in a mouse model of Parkinsons disease," Journal of Neuroscience, vol. 34, no. 6, pp. 2037-2050, 2014.
40. L. Wang, U. Das, D. A. Scott, Y. Tang, P. McLean, and S. Roy, "α-synuclein multimers cluster synaptic vesicles and attenuate recycling," Current Biology, vol. 24, no. 19, pp. 2319-2326, 2014.
41. A. Bellucci, G. Collo, I. Sarnico, L. Battistin, C. Missale, and P. Spano, "Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation," Journal of Neurochemistry, vol. 106, no. 2, pp. 560-577, 2008.
42. A. Bellucci, L. Navarria, E. Falarti et al. , "Redistribution of DAT/α-synuclein complexes visualized by in situ proximity ligation assay in transgenic mice modelling early Parkinsons disease," PLoS ONE, vol. 6, no. 12, Article IDe27959, 2011.
43. A. Sidhu, C. Wersinger, and P. Vernier, "α-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinsons disease," FEBS Letters, vol. 565, no. 1-3, pp. 1-5, 2004.
44. G. G. Kovacs, I. J. Milenkovic, M. Preusser, and H. Budka, "Nigral burden of α-synuclein correlates with striatal dopamine deficit," Movement Disorders, vol. 23,no. 11, pp. 1608-1612, 2008.
45. P. Garcia-Reitbock, O. Anichtchik, A. Bellucci et al. , "SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinsons disease," Brain, vol. 133, part 7, pp. 2032-2044, 2010.
46. K. J. Vargas, S. Makani, T. Davis, C. H. Westphal, P. E. Castillo, and S. S. Chandra, "Synucleins regulate the kinetics of synaptic vesicle endocytosis,"The Journal of Neuroscience, vol. 34, no. 28, pp. 9364-9376, 2014.
47. L. Yavich, H. Tanila, S. Vepsalainen, and P. Jakala, "Role of alpha-synuclein in presynaptic dopamine recruitment," Journal of Neuroscience, vol. 24, no. 49, pp. 11165-11170, 2004.
48. S. Chandra, G. Gallardo, R. Fernandez-Chacon, O. M. Schluter, and T. C. Sudhof, "α-synuclein cooperates with CSPα in preventing neurodegeneration," Cell, vol. 123, no. 3, pp. 383-396, 2005.
49. A. Bellucci, M. Zaltieri, L. Navarria, J. Grigoletto, C. Missale, and P. Spano, "From α-synuclein to synaptic dysfunctions: new insights into the pathophysiology of Parkinsons disease," Brain Research, vol. 1476, pp. 183-202, 2012.
50. M. R. Cookson, "The biochemistry of Parkinsons disease," Annual Review of Biochemistry, vol. 74, pp. 29-52, 2005.
51. D. Games, P. Seubert, E. Rockenstein et al. , "Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of c-terminal-truncated α-synuclein," American Journal of Pathology, vol. 182, no. 3, pp. 940-953, 2013.
52. B. H. Hunn, S. J. Cragg, J. P. Bolam, M. G. Spillantini, and R. Wade-Martins, "Impaired intracellular trafficking defines early Parkinsons disease," Trends in Neurosciences, vol. 38, no. 3, pp. 178-188, 2015.
53. M. N. Gaugler, O. Genc, W. Bobela et al. , "Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity," Acta Neuropathologica, vol. 123, no. 5, pp. 653-669, 2012.
54. V. M. Nemani, W. Lu, V. Berge et al., "Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis," Neuron, vol. 65, no. 1, pp. 66-79, 2010.
55. M. Furlong, C. M. Tanner, S. M. Goldman et al. , "Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinsons disease," Environment International, vol. 75, pp. 144-150, 2015.
56. C. M. Tanner, F. Kame, G. W. Ross et al. , "Rotenone, paraquat, and Parkinsons disease," EnvironmentalHealth Perspectives, vol. 119, no. 6, pp. 866-872, 2011.
57. J. W. Langston and P. A. Ballard Jr. , "Parkinsons disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine," The New England Journal of Medicine, vol. 309, no. 5, article 310, 1983.
58. M. Chen, T. Wang, F. Yue et al. , "Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation inMPTP-intoxicated parkinsonianmonkeys," Neuroscience, vol. 286, pp. 383-392, 2015.
59. A. L. McCormack, S. K. Mak, M. Shenasa, W. J. Langston, L. S. Forno, and D. A. Di Monte, "Pathologic modifications of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys," Journal of Neuropathology and Experimental Neurology, vol. 67, no. 8, pp. 793-802, 2008.
60. G. Vivacqua, F. Biagioni, S. Yu et al. , "Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice," Journal of Chemical Neuroanatomy, vol. 44, no. 2, pp. 76-85, 2012.
61. D. Caparros-Lefebvre and A. Elbaz, "Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group," The Lancet, vol. 354, no. 9175, pp. 281-286, 1999.
62. P. Champy, G. U. Hoglinger, J. Feger et al. , "Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe," Journal of Neurochemistry, vol. 88, no. 1, pp. 63-69, 2004.
63. C. Freire and S. Koifman, "Pesticide exposure and Parkinsons disease: epidemiological evidence of association," NeuroToxicology, vol. 33, no. 5, pp. 947-971, 2012.
64. J. T. Greenamyre, R. Betarbet, and T. B. Sherer, "The rotenone model of Parkinsons disease: genes, environment and mitochondria," Parkinsonism and Related Disorders, vol. 9, supplement 2, pp. S59-S64, 2003.
65. M. Inden, Y. Kitamura, M. Abe, A. Tamaki, K. Takata, and T. Taniguchi, "Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice," Biological and Pharmaceutical Bulletin, vol. 34, no. 1, pp. 92-96, 2011.
66. A. Lannuzel, P. P. Michel, G. U. Hoglinger et al. , "Themitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism," Neuroscience, vol. 121, no. 2, pp. 287-296, 2003.
67. J. Zhu and C. T. Chu, "Mitochondrial dysfunction in Parkinsons disease," Journal of Alzheimers Disease, vol. 20, supplement 2, pp. S325-S334, 2010.
68. G. Ahlqvist, S. Landin, and R. Wroblewski, "Ultrastructure of skeletal muscle in patients with Parkinsons disease and upper motor lesions," Laboratory Investigation, vol. 32, no. 5, pp. 673-679, 1975.
69. L. A. Bindoff, M. A. Birch-Machin, N. E. F. Cartlidge, W. D. Parker Jr. , and D. M. Turnbull, "Respiratory chain abnormalities in skeletal muscle from patients with Parkinsons disease," Journal of the Neurological Sciences, vol. 104, no. 2, pp. 203-208, 1991.
70. C. I. Blake, E. Spitz, M. Leehey, B. J. Hoffer, and S. J. Boyson, "Platelet mitochondrial respiratory chain function in Parkinsons disease," Movement Disorders, vol. 12, no. 1, pp. 3-8, 1997.
71. L. F. Burbulla and R. Kruger, "The use of primary human fibroblasts for monitoring mitochondrial phenotypes in the field of Parkinsons disease," Journal of Visualized Experiments, no. 68,Article ID e4228, 2012.
72. R. H. Haas, F. Nasirian, K. Nakano et al. , "Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinsons disease," Annals of Neurology, vol. 37, no. 6, pp. 714-722, 1995.
73. P. M. Keeney, J. Xie, R. A. Capaldi, and J. P. Bennett Jr. , "Parkinsons disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled," The Journal of Neuroscience, vol. 26, no. 19, pp. 5256-5264, 2006.
74. M. Muftuoglu, B. Elibol, O. Dalmizrak et al. , "Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations," Movement Disorders, vol. 19, no. 5, pp. 544-548, 2004.
75. C. van der Merwe, B. Loos, C. Swart et al. , "Mitochondrial impairment observed in fibroblasts fromSouth African Parkinsons disease patients with parkin mutations," Biochemical and Biophysical Research Communications, vol. 447, no. 2, pp. 334-340, 2014.
76. H. Yoshino, Y. Nakagawa-Hattori, T. Kondo, and Y. Mizuno, "Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinsons disease," Journal of Neural Transmission: Parkinsons Disease and Dementia Section, vol. 4, no. 1, pp. 27-34, 1992.
77. G. Ashrafi and T. L. Schwarz, "The pathways of mitophagy for quality control and clearance of mitochondria," Cell Death and Differentiation, vol. 20, no. 1, pp. 31-42, 2013.
78. H. Deng, M. W. Dodson, H. Huang, and M. Guo, "The Parkinsons disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14503-14508, 2008.
79. H. Koh and J. Chung, "PINK1 as a molecular checkpoint in the maintenance of mitochondrial function and integrity," Molecules and Cells, vol. 34, no. 1, pp. 7-13, 2012.
80. D. Narendra, J. E. Walker, and R. Youle, "Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism," Cold Spring Harbor Perspectives in Biology, vol. 4, no. 11, 2012.
81. P. M. Abou-Sleiman, M. M. K. Muqit, N. Q. McDonald et al. , "A heterozygous effect for PINK1 mutations in Parkinsons disease?" Annals of Neurology, vol. 60, no. 4, pp. 414-419, 2006.
82. E. M. Valente, P. M. Abou-Sleiman, V. Caputo et al. , "Hereditary early-onset Parkinsons disease caused by mutations in PINK1," Science, vol. 304, no. 5674, pp. 1158-1160, 2004.
83. N. Hattori, M. Tanaka, T. Ozawa, and Y. Mizuno, "Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinsons disease," Annals of Neurology, vol. 30, no. 4, pp. 563-571, 1991.
84. D. Krige, M. T. Carroll, J. M. Cooper, C. D. Marsden, and A. H. V. Schapira, "Platelet mitochondrial function in Parkinsons disease," Annals of Neurology, vol. 32, no. 6, pp. 782-788, 1992.
85. W. D. Parker Jr. , J. K. Parks, and R. H. Swerdlow, "Complex I deficiency in Parkinsons disease frontal cortex," Brain Research, vol. 1189, no. 1, pp. 215-218, 2008.
86. A. H. V. Schapira, "Evidence for mitochondrial dysfunction in Parkinsons disease-a critical appraisal," Movement Disorders, vol. 9, no. 2, pp. 125-138, 1994.
87. M. Piert, R. A. Koeppe, B. Giordani, S. Minoshima, and D. E. Kuhl, "Determination of regional rate constants from dynamic FDG-PET studies in Parkinsons disease," Journal of Nuclear Medicine, vol. 37, no. 7, pp. 1115-1122, 1996.
88. M. Rango, C. Bonifati, and N. Bresolin, "Parkinsons disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study," Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 2, pp. 283-290, 2006.
89. W. J. Powers, T. O. Videen, J. Markham, K. J. Black, N. Golchin, and J. S. Perlmutter, "Cerebral mitochondrial metabolism in early Parkinsons disease," Journal of Cerebral Blood Flow and Metabolism, vol. 28, no. 10, pp. 1754-1760, 2008.
90. M. Ikawa, H. Okazawa, T. Kudo, M. Kuriyama, Y. Fujibayashi, and M. Yoneda, "Evaluation of striatal oxidative stress in patients with Parkinsons disease using [62Cu]ATSM PET," Nuclear Medicine and Biology, vol. 38, no. 7, pp. 945-951, 2011.
91. V. Rangaraju,N. Calloway, and T. A. Ryan, "Activity-driven local ATP synthesis is required for synaptic function," Cell, vol. 156, no. 4, pp. 825-835, 2014.
92. V. Dias, E. Junn, and M. M. Mouradian, "The role of oxidative stress in parkinsons disease," Journal of Parkinsons Disease, vol. 3, no. 4, pp. 461-491, 2013.
93. J. Follett, B. Darlow, M. B. Wong, J. Goodwin, and D. L. Pountney, "Potassium depolarization and raised calcium induces alpha-synuclein aggregates," Neurotoxicity Research, vol. 23, no. 4, pp. 378-392, 2013.
94. J. Goodwin, S. Nath, Y. Engelborghs, and D. L. Pountney, "Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation," Neurochemistry International, vol. 62, no. 5, pp. 703-711, 2013.
95. S. Nath, J. Goodwin, Y. Engelborghs, and D. L. Pountney, "Raised calcium promotes α-synuclein aggregate formation," Molecular and Cellular Neuroscience, vol. 46, no. 2, pp. 516-526, 2011.
96. T. Cali, D. Ottolini, A. Negro, and M. Brini, "α-synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions," The Journal of Biological Chemistry, vol. 287, no. 22, pp. 17914-17929, 2012.
97. K. M. Danzer, D. Haasen, A. R. Karow et al. , "Different species of α-synuclein oligomers induce calcium influx and seeding," The Journal of Neuroscience, vol. 27, no. 34, pp. 9220-9232, 2007.
98. C. E. Ellis, E. J. Murphy, D. C. Mitchell et al. , "Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking α-synuclein," Molecular and Cellular Biology, vol. 25, no. 22, pp. 10190-10201, 2005.
99. I. Ferrer, A. Martinez, R. Blanco, E. Dalfo, and M. Carmona, "Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease," Journal of Neural Transmission, vol. 118, no. 5, pp. 821-839, 2011.
100. S. K. Muller, A. Bender, C. Laub et al. , "Lewy body pathology is associated with mitochondrial DNA damage in Parkinsons disease," Neurobiology of Aging, vol. 34, no. 9, pp. 2231-2233, 2013.
101. L. Devi, V. Raghavendran, B. M. Prabhu, N. G. Avadhani, and H. K. Anandatheerthavarada, "Mitochondrial import and accumulation of α-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain," The Journal of Biological Chemistry, vol. 283, no. 14, pp. 9089-9100, 2008.
102. L. J. Hsu, Y. Sagara, A. Arroyo et al. , "alpha-synuclein promotes mitochondrial deficit and oxidative stress," The American Journal of Pathology, vol. 157, no. 2, pp. 401-410, 2000.
103. K. Nakamura, V. M. Nemani, F. Azarbal et al. , "Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein α-synuclein," The Journal of Biological Chemistry, vol. 286, no. 23, pp. 20710-20726, 2011.
104. F. Kamp,N. Exner, A. K. Lutz et al. , "Inhibition ofmitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1," EMBO Journal, vol. 29, no. 20, pp. 3571-3589, 2010.
105. C. Guardia-Laguarta, E. Area-Gomez, C. Rub et al. , "α-synuclein is localized to mitochondria-associated ER membranes," The Journal of Neuroscience, vol. 34, no. 1, pp. 249-259, 2014.
106. M. Zhu,W. Li, and C. Lu, "Role of alpha-synuclein protein levels in mitochondrial morphology and cell survival in cell lines," PLoS ONE, vol. 7, no. 4,Article ID e36377, 2012.
107. A. Bir, O. Sen, S. Anand et al. , "α-synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinsons disease," Journal of Neurochemistry, vol. 131, no. 6, pp. 868-877, 2014.
108. R. Perfeito, D. F. Lazaro, T. F. Outeiro, and A. C. Rego, "Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells," Molecular and Cellular Neuroscience, vol. 62, pp. 51-59, 2014.
109. L. Li, S. Nadanaciva, Z. Berger et al. , "Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons," PLoS ONE, vol. 8, no. 12, Article ID e85815, 2013.
110. A. Bender, P. Desplats, B. Spencer et al. , "TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinsons disease," PLoS ONE, vol. 8, no. 4, Article ID e62277, 2013.
111. S. R. Subramaniam, L. Vergnes, N. R. Franich, K. Reue, and M. Chesselet, "Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein," Neurobiology of Disease, vol. 70, pp. 204-213, 2014.
112. W. Dauer, N. Kholodilov, M. Vila et al. , "Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14524-14529, 2002.
113. P. Klivenyi, D. Siwek, G. Gardian et al. , "Mice lacking alphasynuclein are resistant to mitochondrial toxins," Neurobiology of Disease, vol. 21, no. 3, pp. 541-548, 2006.
114. O. M. Schluter, F. Fornai, M. G. Alessandri et al. , "Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineinduced Parkinsonism in mice," Neuroscience, vol. 118, no. 4, pp. 985-1002, 2003.
115. Y. Imaizumi, Y. Okada, W. Akamatsu et al. , "Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue," Molecular Brain, vol. 5, no. 1, article 35, 2012.
116. L. J. Martin, Y. Pan, A. C. Price et al. , "Parkinsons disease α-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death," The Journal of Neuroscience, vol. 26, no. 1, pp. 41-50, 2006.
117. A. R. Esteves, D. M. Arduino, R. H. Swerdlow, C. R. Oliveira, and S. M. Cardoso, "Microtubule depolymerization potentiates alpha-synuclein oligomerization," Frontiers in Aging Neuroscience, vol. 1, article 5, 2010.
118. A. R. Esteves, I. Gozes, and S. M. Cardoso, "The rescue of microtubule-dependent traffic recoversmitochondrial function in Parkinsons disease," Biochimica et Biophysica Acta:Molecular Basis of Disease, vol. 1842, no. 1, pp. 7-21, 2014.
119. O. Chutna, S. Goncalves, A. Villar-Pique et al. , "The small GTPase Rab11 co-localizes with α-synuclein in intracellular inclusions and modulates its aggregation, secretion and toxicity," Human Molecular Genetics, vol. 23, no. 25, pp. 6732-6745, 2014.
120. E. Dalfo and I. Ferrer, "Alpha-synuclein binding to rab3a in multiple system atrophy," Neuroscience Letters, vol. 380, no. 1-2, pp. 170-175, 2005.
121. S. Nakamura, Y. Kawamoto, S. Nakano, and I. Akiguchi, "Expression of the endocytosis regulatory proteins Rab5 and Rabaptin-5 in glial cytoplasmic inclusions from brains with multiple system atrophy," Clinical Neuropathology, vol. 19, no. 2, pp. 51-56, 2000.
122. S. R. Pfeffer, "Rab GTPases: master regulators of membrane trafficking," Current Opinion in Cell Biology, vol. 6, no. 4, pp. 522-526, 1994.
123. C. O. Davis, K. Kim, E. A. Bushong et al. , "Transcellular degradation of axonal mitochondria," Proceedings of the National Academy of Sciences, vol. 111, no. 26, pp. 9633-9638, 2014.
124. K. Hayashida, S. Oyanagi, Y. Mizutani, and M. Yokochi, "An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism," Acta Neuropathologica, vol. 85, no. 4, pp. 445-448, 1993.
125. J. R. Cannon, V. Tapias, H. M. Na, A. S. Honick, R. E. Drolet, and J. T. Greenamyre, "A highly reproducible rotenone model of Parkinsons disease," Neurobiology of Disease, vol. 34, no. 2, pp. 279-290, 2009.
126. R. E. Drolet, J. R. Cannon, L. Montero, and J. T. Greenamyre, "Chronic rotenone exposure reproduces Parkinsons disease gastrointestinal neuropathology," Neurobiology of Disease, vol. 36, no. 1, pp. 96-102, 2009.
127. S. Mandel, G. Maor, and M. B. H. Youdim, "Iron and α-synuclein in the substantia nigra ofMPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate," Journal ofMolecular Neuroscience, vol. 24, no. 3, pp. 401-416, 2004.
128. F. Pan-Montojo, M. Schwarz, C. Winkler et al. , "Environmental toxins trigger PD-like progression via increased alphasynuclein release from enteric neurons in mice," Scientific Reports, vol. 2, article 898, 2012.
129. F. J. Pan-Montojo and R. H. W. Funk, "Oral administration of rotenone using a gavage and image analysis of alpha-synuclein inclusions in the enteric nervous system," Journal of Visualized Experiments, no. 44, article 2123, 2010.
130. F. S. M. Tristao, M. Amar, I. Latrous, E. A. Del-Bel, R. D. Prediger, and R. Raisman-Vozari, "Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinsons disease," Neurotoxicity Research, vol. 25, no. 1, pp. 24-32, 2014.
131. J. Wing-Man Ho, P. Wing-Lok Ho, H.-F. Liu et al. , "UCP4 is a target effector of the NF-κB c-Rel prosurvival pathway against oxidative stress," Free Radical Biology and Medicine, vol. 53, no. 2, pp. 383-394, 2012.
132. C. Baiguera, M. Alghisi, A. Pinna et al. , "Late-onset Parkinsonism in NFkappaB/c-Rel-deficient mice," Brain, vol. 135, no. 9, pp. 2750-2765, 2012.
133. E. Mendoza, J. Miranda-Barrientos, R. Vazquez-Roque et al. , "In vivo mitochondrial inhibition alters corticostriatal synaptic function and the modulatory effects of neurotrophins," Neuroscience, vol. 280, pp. 156-170, 2014.
134. Y. Nakata, T. Yasuda, M. Fukaya et al. , "Accumulation of α-synuclein triggered by presynaptic dysfunction," The Journal of Neuroscience, vol. 32, no. 48, pp. 17186-17196, 2012.
135. K. Obashi and S. Okabe, "Regulation of mitochondrial dynamics and distribution by synapse position and neuronal activity in the axon," European Journal of Neuroscience, vol. 38, no. 3, pp. 2350-2363, 2013.
136. N. Ishihara,M. Nomura, A. Jofuku et al. , "Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice," Nature Cell Biology, vol. 11, no. 8, pp. 958-966, 2009.